OJEMDA Trademark

Trademark Overview


On Tuesday, June 6, 2023, a trademark application was filed for OJEMDA with the United States Patent and Trademark Office. The USPTO has given the OJEMDA trademark a serial number of 98030463. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, September 3, 2024. This trademark is owned by Day One Biopharmaceuticals, Inc.. The OJEMDA trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical preparations for human use for the treatment of cancer; pharmaceutical preparation for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of oncological diseases; pharmaceutical preparations and substances for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders; targeted pharmaceutical preparations for use in the field of cancer prevention and treatment; pharmaceutical and veterinary preparations for the delivery of compounds to the body for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, derma...

Medical information services; healthcare services, namely, providing cancer treatment information to physicians, health care professionals, and patients; medical information services, namely, providing information regarding viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders

Research, development, and product evaluation of pharmaceutical preparations for the prevention and treatment of cancer; laboratory analysis and research of drugs and pharmaceutical products; research and development services in the fields of oncology, immunotherapy, chemotherapy, and combination therapies for the treatment of cancer and tumors; providing medical research information in the fields of oncology, immunotherapy, chemotherapy and combination therapies; scientific advisory services, namely, providing scientific information, advice, and consultancy in the field of cancer treatment; design, development, research, and testing of new products, namely, drugs and pharmaceuticals for the treatment and/or prevention of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and ...
ojemda

General Information


Serial Number98030463
Word MarkOJEMDA
Filing DateTuesday, June 6, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, September 3, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 9, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment of cancer; pharmaceutical preparation for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of oncological diseases; pharmaceutical preparations and substances for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders; targeted pharmaceutical preparations for use in the field of cancer prevention and treatment; pharmaceutical and veterinary preparations for the delivery of compounds to the body for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
Goods and ServicesMedical information services; healthcare services, namely, providing cancer treatment information to physicians, health care professionals, and patients; medical information services, namely, providing information regarding viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders
Goods and ServicesResearch, development, and product evaluation of pharmaceutical preparations for the prevention and treatment of cancer; laboratory analysis and research of drugs and pharmaceutical products; research and development services in the fields of oncology, immunotherapy, chemotherapy, and combination therapies for the treatment of cancer and tumors; providing medical research information in the fields of oncology, immunotherapy, chemotherapy and combination therapies; scientific advisory services, namely, providing scientific information, advice, and consultancy in the field of cancer treatment; design, development, research, and testing of new products, namely, drugs and pharmaceuticals for the treatment and/or prevention of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, July 11, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, July 11, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, July 11, 2023
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameDay One Biopharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBrisbane, CA 94005

Party NameDay One Biopharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBrisbane, CA 94005

Trademark Events


Event DateEvent Description
Friday, June 9, 2023NEW APPLICATION ENTERED
Tuesday, July 11, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 27, 2024ASSIGNED TO EXAMINER
Monday, March 4, 2024NON-FINAL ACTION WRITTEN
Monday, March 4, 2024NON-FINAL ACTION E-MAILED
Monday, March 4, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, May 31, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, May 31, 2024EXAMINERS AMENDMENT -WRITTEN
Friday, May 31, 2024EXAMINERS AMENDMENT E-MAILED
Friday, May 31, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, May 31, 2024EXAMINER'S AMENDMENT ENTERED
Wednesday, June 19, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 9, 2024PUBLISHED FOR OPPOSITION
Tuesday, July 9, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 3, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT